A prospective investigation of chemotherapy-induced neutropenia and quality of life

Journal of Supportive Oncology

Volumn 4, Issue 9, 2006, Pages 472-478

  Fortner, Barry V ^a   Houts, Arthur C ^a   Schwartzberg, Lee S ^a  

^a Supportive Oncology Services Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; NEUTROPENIA; NEUTROPHIL COUNT; PROSPECTIVE STUDY; QUALITY OF LIFE; SHORT FORM 36; SOCIAL INTERACTION; SYMPTOM;

ADAPTATION, PSYCHOLOGICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANXIETY; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEPRESSION; DOXORUBICIN; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PREDNISONE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; QUALITY OF LIFE; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; TAXOIDS; TREATMENT OUTCOME; UNITED STATES; VINCRISTINE;

EID: 33750708853     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Adams JR, Lyman GH, Djubegovic B, Feinglass J, Bennett CL.G-CSF as prophylaxis of febrile neutropenia in SCLC. Expert Opin Pharmacother 2002;3:1273-1281.
2. Cappozzo C. Optimal use of granulocyte-colony-stimulating factor in patients with cancer who are at risk for chemotherapy-induced neutropenia. Oncol Nurs Forum 2004;31:569-576.
3. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228-237.
4. Leonard RC, Miles D, Thomas R, Nussey F; UK Breast Cancer Neutropenia Audit Group. Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer 2003;89:2062-2068.
5. Minisini A, Spazzapan S, Crivellari D, Aapro M, Biganzoli L. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors. Crit Rev Oncol Hematol 2005;53:125-131.
6. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Washington DC, 2003. Available at: http://ctep.cancer.gov/forms/CTCAEv3.pdf. Accessed June 27, 2006.
7. Blackwell S, Crawford J. Colony-stimulating factors: clinical applications. Pharmacotherapy 1992;12:20S-31S.
8. Alexander SW, Pizzo PA. Current considerations in the management of fever and neutropenia. Curr Clin Top Infect Dis 1999;19:160-180.
9. Balducci L, Tam J, Al-Halawani H, et al. A large study of the older cancer patient in the community setting: initial report of a randomized controlled trial using pegfilgrastim to reduce neutropenic complications. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology. May 13-17, 2005; Orlando, Fla. Abstract 8111.
10. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-340.
11. Lehrnbecher T, Chanock SJ. Controversies in the treatment of neutropenia in cancer patients. Curr Opin Hematol 1998;5:26-32.
12. Meza L, Baselga J, Holmes FA, Liang B, Breddy J. Incidence of febrile neutropenia is directly related to duration of severe neutropenia after myelosuppressive chemotherapy. Presented at the 38th Annual Meeting of the American Society of Clinical Oncology; May 18-21, 2002; Orlando, Fla. Abstract 2840.
13. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992;80:1430-1436.
14. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-1332.
15. Glaspy J, Hackett J, Flyer P, Dunford D, Liang B. Febrile neutropenia is associated with an increase in the incidence, duration, and severity of chemotherapy toxicities. Presented at the 43rd Annual Meeting of the American Society of Hematology; December 7-11, 2001; Orlando, Fla. Abstract 1812.
16. Fortner BV, Schwartzberg L, Tauer K, Houts AC, Hackett J, Stolshek BS. Impact of chemotherapy-induced neutropenia on quality of life: a prospective pilot investigation. Support Care Cancer 2005;13:522-528.
17. de Haes JCJM, Olschewski M, Fayers PM, et al. The Rotterdam Symptom Checklist (RSCL). Groningen, The Netherlands: Northern Centre for Healthcare Research (NCH); 1996
18. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute New England Medical Center; 1993.
19. Ware JE, Kosinski MA. The SF-36 Physical and Mental Health Summary Scales: A Manual for Users of Version 1.2nd ed. Lincoln, RI: QualityMetric, Inc; 2001.
20. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale: an updated literature review. J Psychosom Res 2002;52:69-77.
21. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370.
22. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models. Cary, NC: SAS Institute Inc; 2002.
23. Fortner BV, Durrence HH, Schwartzberg LS, Houts AC. Validation of the Functional Assessment of Cancer Therapy-Neutropenia (FACT-N) and the Cancer Care Monitor-Neutropenia Index (CCM-N). Presented at the 45th Annual Meeting of the American Society of Hematology; December 6-9, 2003; San Diego, Calif. Abstract 1807.
24. Fortner BV, Schwartzberg LS, Houts AC. Greater physical and psychological symptom burden in patients with grades 3 and 4 chemotherapy-induced neutropenia. Support Cancer Ther. In press.
25. Lyman GH, Kuderer NM. Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs 2002;62(suppl):65-78.
26. Padilla G, Ropka ME. Quality of life and chemotherapy-induced neutropenia. Cancer Nurs 2005;28:167-171.
27. Martin M, Lluch A, Segui MA, et al. Toxicity and health-related quality of life in node-negative breast cancer patients receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC (5-fluorouracil, doxorubicin, cyclophosphamide): impact of adding prophylactic growth factors to TAC, GEICAM Study 9805. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 604.
28. Lehmann EL, Romano JP. Generalizations of the familywise error rate. Ann Stat 2005;33:1138-1154.